

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT

Mandi Foam of 3SBio approved for market launch

3SBio Inc. (the “**Company**”) wishes to provide to the shareholders of the Company the attached press release in respect of the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co., Ltd., to the National Medical Products Administration (NMPA) of the PRC being approved.

This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully develop, launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Shenyang, the PRC
8 January 2024

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin as non-executive Director; and Mr. PU Tianruo, Ms. YANG, Hoi Ti Heidi, Mr. NG, Joo Yeow Gerry, and Dr. ZHANG Dan as independent non-executive Directors.

Mandi Foam of 3SBio approved for market launch

Leading Chinese biopharmaceutical company 3SBio Inc. (01530.HK) announced today that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co., Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved.

Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in “a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability” reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®.

Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users.

Dr. LOU Jing, Chairman and CEO of 3SBio Inc., commented, “3SBio Inc. has always focused on therapeutical fields with urgent clinical needs, continuously launching high-quality drugs to the market. China has a huge population of hair loss patients, with androgenetic alopecia being the most common. The launch of Mandi Foam will further enrich the drug options for hair loss patients and consolidate the leading position of 3SBio Inc. in the field of hair loss treatment.”

About 3SBio Inc.

3SBio Inc. is a leading biopharmaceutical company integrating research and development (“R&D”), production and sales, with a focus on improving the life quality of patients with high quality medicines to benefit human health. At present, the Group owns more than 100 national invention patents and has launched more than 40 products into the market, covering several treatment fields, including, among others, nephrology, oncology, autoimmune, ophthalmology and dermatology. The Group includes the National Engineering Research Center of Antibody Medicine and four R&D bases with dual platforms for biopharmaceutical and chemical medicines. Amongst the 30 product candidates within the Group’s active pipeline, 25 are being developed as innovative drugs in mainland China. The Group also owns five production bases that are GMP-compliant. In the future, 3SBio Inc. will continue to uphold the vision of “Care for Life, Cherish Life, Create Life” to build a world-leading biopharmaceutical company in China. Please visit www.3sbio.com for additional information.

Cautionary Notes and Forward-Looking Statements

This press release contains forward-looking statements, such as those relating to business and product outlook, or the Company's intent, plans, beliefs, expectation and strategies. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. These forward-looking statements are based on certain expectations, assumptions and premises, some of which are subjective or beyond our control. These forward-looking statements may prove to be incorrect or may not be realized in the future. With respect to any new product or new indication for a product, we cannot guarantee that it will be successfully developed or ultimately marketed. Such forward-looking statements are subject to various risks and uncertainties. Further information regarding such risks and uncertainties may be found in our other public disclosure documents. The scientific information involved may only be preliminary and empirical. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.